Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00325897 · ClinicalTrials.gov registry record · NA
Macrolide Azithromycin to Prevent Rapid Worsening of Symptoms Associated With Chronic Obstructive Pulmonary Disease
A NA study, sponsored by University of Minnesota.
- Completed
- Registry status
- NA
- Development phase
- 1,142
- Enrollment target
NCT00325897: Completed NA study, sponsored by University of Minnesota.
NCT00325897 is a NA study that has completed, run by University of Minnesota. The registered enrollment target is 1,142 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (19% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00325897, a NA study, has completed, sponsored by University of Minnesota.
- COMPLETED
- Registry status
- NA
- Development phase
- 1,142 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if long-term administration of a macrolide antibiotic will reduce worsening of symptoms among individuals with chronic obstructive pulmonary disease (COPD).
Primary Outcome
Time until first occurrence of acute Chronic Obstructive Pulmonary Disease (COPD) exacerbation. Acute exacerbations are defined as a "complex of respiratory symptoms (increase or new onset) of more than one of the following: cough, sputum, wheezing, dyspnea, or chest tightness with a duration of at least three days requiring treatment with antibiotics and/or systemic steroids "
Interventions
- DRUG Placebo
- DRUG Macrolide Antibiotic (Azithromycin)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,142 participants |
| Start Date | 2006-03 |
| Est. Completion | 2010-07 |
| Phase | NA |
What the finished NCT00325897 record still lists
NCT00325897 is an interventional study that assigns participants to a tested intervention. Its 1,142 participants enrollment target places it among the larger protocols in the corpus, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (19% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00325897 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00325897 about?
NCT00325897 is a clinical study titled "Macrolide Azithromycin to Prevent Rapid Worsening of Symptoms Associated With Chronic Obstructive Pulmonary Disease". The purpose of this study is to determine if long-term administration of a macrolide antibiotic will reduce worsening of symptoms among individuals with chronic obstructive pulmonary disease (COPD).
What is the current status of trial NCT00325897?
This trial is currently completed. It is a NA study. The enrollment target is 1,142 participants. The study started on 2006-03. Estimated completion is 2010-07.
What interventions are being tested in trial NCT00325897?
The interventions under investigation include: Placebo (DRUG), Macrolide Antibiotic (Azithromycin) (DRUG).
Who is sponsoring clinical trial NCT00325897?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00325897's enrollment target sits among peer trials
1,142 92nd of 2000 higher than 1,909 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05894967 · 1,140 participants · NA
Moderators and Mediators of Perceptual Learning
- NCT06532487 · 1,140 participants · NA
Addressing Durable Health Disparities Through Critical Time Legal Interventions in Medically Underserved Latinx and Migrant Communities
- NCT06129864 · 1,145 participants · Phase 3
A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy
- NCT06676319 · 1,147 participants · Phase 2
Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia